From the Department of Neuroradiology (A.R., R.H., P.K., P.B., A.S., M.B.) and Neurology Clinic (W.W.), University of Heidelberg Medical Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany (A.R., R.H., P.B., S.B., D.P., H.P.S.); Department of Radiology, German Cancer Consortium (DKTK), Heidelberg, Germany (A.R., R.H.); and Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany (A.R.).
Radiology. 2017 Jun;283(3):828-836. doi: 10.1148/radiol.2017162980. Epub 2017 Mar 8.
Purpose To determine the effect of at least five serial injections of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglumine on the signal intensity (SI) of the dentate nucleus (DN) of the pediatric brain on nonenhanced T1-weighted magnetic resonance (MR) images. Materials and Methods In this retrospective, institutional review board-approved study, 41 pediatric patients (age range, 3-17 years) who were imaged in at least five consecutive 1.5-T MR examinations with the exclusive use of gadoterate meglumine (plus a final additional nonenhanced MR imaging examination) were evaluated. SI ratio differences between the first and last MR examination were calculated for DN-to-pons and DN-to-middle cerebellar peduncle (MCP) ratios in a region-of-interest-based analysis, and one-sample t tests were used to examine if the SI ratio differences differed from 0. Bayes factors were calculated to quantify the strength of evidence for each test. Results Patients underwent a mean of 8.6 ± 3.9 GBCA administrations (mean accumulated dose, 32.07 mmol ± 17.62, with an average of 16.7 weeks ± 7.9 between every administration). Both ratio differences did not differ significantly from 0 (DN-to-pons ratio: -0.0012 ± 0.0101, P = .436; DN-to-MCP ratio: 0.0007 ± 0.0088, P = .604), and one-sided Bayes factors provided substantial evidence against an SI ratio increase (0.10 for DN-to-pons ratio; 0.27 for DN-to-MCP ratio). Conclusion No increase of the SI in the DN was found after a mean of 8.6 serial injections of the macrocyclic GBCA gadoterate meglumine in pediatric patients, confirming previous studies that did not find this effect after serial injections of macrocyclic GBCAs in adults. RSNA, 2017.
目的:确定至少五次连续注射大环类钆对比剂(GBCA)钆特酸葡胺后,儿童脑内齿状核(DN)的信号强度(SI)在未增强 T1 加权磁共振(MR)图像上的变化。
材料与方法:本回顾性研究经机构审查委员会批准,共纳入 41 例连续 5 次 1.5TMR 检查(均使用钆特酸葡胺,末次检查后均行未增强 MR 成像检查)的儿科患者。采用基于感兴趣区的分析方法,计算首次和末次 MR 检查时 DN 与脑桥(DN-to-pons)和 DN 与小脑中脚(DN-to-MCP)比值的 SI 比值差异,采用单样本 t 检验比较 SI 比值差异是否与 0 有差异。计算贝叶斯因子以量化每种检验的证据强度。
结果:患者平均接受 8.6±3.9 次 GBCA 给药(平均累积剂量为 32.07mmol±17.62mmol,每次给药间隔 16.7 周±7.9 周)。两种比值差异均与 0 无显著差异(DN-to-pons 比值:-0.0012±0.0101,P=.436;DN-to-MCP 比值:0.0007±0.0088,P=.604),单侧贝叶斯因子提供了大量证据表明 SI 比值没有增加(DN-to-pons 比值为 0.10;DN-to-MCP 比值为 0.27)。
结论:在儿科患者中,平均进行 8.6 次连续大环类 GBCA 钆特酸葡胺注射后,未发现 DN 的 SI 增加,这与之前的研究结果一致,即在成人中连续使用大环类 GBCA 后并未发现这种效应。
放射学学会,2017 年。
Arch Toxicol. 2025-7-3
J Magn Reson Imaging. 2025-1
Molecules. 2021-12-23
AJNR Am J Neuroradiol. 2021-5
AJNR Am J Neuroradiol. 2019-11-14